Thursday, November 29, 2018

Nature Reviews Drug Discovery contents December 2018 Volume 17 Number 12 pp 845-922

Nature Reviews Drug Discovery


Advertisement
High-Quality Fragments

Enjoy industry leading prices and low error rates on gene fragments.
TABLE OF CONTENTS

December 2018 Volume 17, Issue 12

Comment
News and Analysis
Research Highlights
Reviews
Erratum
Corrigenda

Advertisement
=======================

Register for the latest nature.com webcast

Use of Simoa Planar Protein Multiplex Arrays as a Sensitive Biomarker Platform in Oncology Clinical Trials – Wednesday, December 12, 2018

Register for FREE today

Sponsored by: Quanterix

======================




Advertisement
Johnson & Johnson Innovation is searching for the best and brightest innovators in healthcare! Apply for the exclusive opportunity to present your game-changing idea to J&J leadership during the week of the 37th Annual JP Morgan Healthcare Conference in San Francisco. Don't delay! Applications close December 7.

Learn more about the Quick Pitch and submit applications here.
 
Advertisement

BIOPHARMA DEALMAKERS
BIOPHARMA DEALMAKERSCompany Profiles and Partnering Opportunities


 

Advertisement
Winners announced!

We are delighted to announce the first ever winners of the Nature Research Awards for Inspiring Science and Innovating Science, in partnership with The Estée Lauder Companies. Congratulations to both our Award winners!

See who's won >

In partnership with The Estée Lauder Companies.
 

Comment

The evolution of adaptiveness: balancing speed and evidence   
Hans-Georg Eichler, Richard Barker, Nicola Bedlington, Jacoline C. Bouvy, André W. Broekmans et al.
pp845 - 846 | doi:10.1038/nrd.2018.90
'Adaptive' approaches to bringing drugs to market have been widely discussed in recent years. Here, we describe the evolution of the adaptive approach and of concepts developed by ADAPT SMART, a multi-stakeholder consortium funded by the European Innovative Medicines Initiative.
Full Text | PDF



News and Analysis

Phosphatases start shedding their stigma of undruggability   
Asher Mullard
pp847 - 849 | doi:10.1038/nrd.2018.201
Clinical-stage allosterically acting drugs are on track to unlock a stubborn class of targets.
Full Text | PDF
Collection: Cancer at Nature Research


FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on   
Asher Mullard
pp850 - 851 | doi:10.1038/nrd.2018.206
A panel of independent experts voted narrowly in favour of continuing to require cardiovascular outcomes data for new diabetes drugs, but urged relaxation and simplification of the safety assessment.
Full Text | PDF



News in Brief
Anti-inflammatory cardiovascular therapies take another hit   
Asher Mullard
p853 | doi:10.1038/nrd.2018.218
Full Text | PDF



FDA approves first new flu drug in 20 years   
Asher Mullard
p853 | doi:10.1038/nrd.2018.219
Full Text | PDF



RNAi deal flow heats up   
Asher Mullard
p853 | doi:10.1038/nrd.2018.220
Full Text | PDF



Biobusiness Briefs
Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors   
Jun Tang, Jia Xin Yu, Vanessa M. Hubbard-Lucey, Svetoslav T. Neftelinov, Jeffrey P. Hodge et al.
pp854 - 855 | doi:10.1038/nrd.2018.210
Full Text | PDF
Collection: Cancer at Nature Research


Market watch: The industry's biggest drug launches   
Lisa Urquhart
p855 | doi:10.1038/nrd.2018.209
Full Text | PDF
Collection: Cancer at Nature Research


An Audience With
Samantha Du   
pp856 - 857 | doi:10.1038/nrd.2018.208
Samantha Du, CEO of Zai Lab and former CSO of Chi-Med, talks about the burgeoning Chinese biopharma ecosystem.
Full Text | PDF



From the analyst's couch
Reforming China's drug regulatory system   
Lili Xu, Huijun Gao, Kenneth I. Kaitin & Liming Shao
pp858 - 859 | doi:10.1038/nrd.2018.150
Since 2015, the Chinese government has introduced numerous reforms with the aim of establishing a more scientific and efficient drug regulatory system, which are highlighted here.
Full Text | PDF



Advertisement
Searching for a new career?

At Nature Research we frequently recruit talented individuals to join our editorial and publishing teams. If you have a PhD and a passion for science this may be the perfect career for you.

Visit our research editorial and publishing careers website to discover more about what we do
 

Research Highlights

Metabolic disease: Safely mimicking cold exposure to reverse obesity
Sarah Crunkhorn
p861 | doi:10.1038/nrd.2018.211
PDF



Anticancer therapy: Complementing tumour macrophage reprogramming
M. Teresa Villanueva
p862 | doi:10.1038/nrd.2018.216
PDF



Anticancer drugs: Translational target for checkpoint inhibitors
Katie Kingwell
p863 | doi:10.1038/nrd.2018.204
PDF



Antifungal drugs: Small molecules targeting a tertiary RNA structure fight fungi
Megan Cully
p864 | doi:10.1038/nrd.2018.205
PDF



In Brief
Aging: Promoting NAD+ production
Sarah Crunkhorn
p864 | doi:10.1038/nrd.2018.212
PDF



Drug repurposing: Heart failure drug effective in medulloblastoma
Sarah Crunkhorn
p864 | doi:10.1038/nrd.2018.213
PDF



Cancer: Redirecting T cell activity in solid tumours
Sarah Crunkhorn
p864 | doi:10.1038/nrd.2018.214
PDF



Type 2 diabetes: Microbial metabolite impairs insulin signaling
Sarah Crunkhorn
p864 | doi:10.1038/nrd.2018.215
PDF



Drug Discovery
EVENT
4th Drug Discovery Re-Invented Conference
21.02.19
Nassau, Bahamas
More science events from
Advertisement
Why is innate immunity an under-appreciated aspect of immunotherapy?

Researchers have now identified methods to elicit the innate immune system to exhibit heightened anti-infective activity while at the same time decreasing the inflammatory response.

Could this offer a new approach for immunotherapy? Read more here >>

In association with Soligenix
 

Reviews

Mitochondria as a therapeutic target for common pathologies   
Michael P. Murphy & Richard C. Hartley
pp865 - 886 | doi:10.1038/nrd.2018.174
Mitochondrial dysfunction contributes to many common disorders, and therapeutic strategies aimed at restoring mitochondrial function are now emerging, with a small number of agents now in clinical trials. Here, Murphy and Hartley assess therapeutic approaches and challenges in targeting mitochondria and highlight examples of promising indications.
Full Text | PDF



Targeting macrophages: therapeutic approaches in cancer   
Luca Cassetta & Jeffrey W. Pollard
pp887 - 904 | doi:10.1038/nrd.2018.169
Tumour-associated macrophages (TAMs) promote cancer initiation and malignant progression. This Review evaluates current strategies to target TAMs, exploring their toxicity and compensatory mechanisms, and proposes novel strategies in light of new findings regarding macrophage biology and their mechanism of action.
Full Text | PDF



Therapeutic strategies targeting connexins   
Dale W. Laird & Paul D. Lampe
pp905 - 921 | doi:10.1038/nrd.2018.138
The connexin family of channel-forming proteins is critical for cellular communication, being involved in both health and disease. Here, Laird and Lampe assess the potential of connexins as therapeutic targets in acquired and inherited diseases, as well as wound repair, highlighting agents currently in development and the associated clinical challenges.
Full Text | PDF



Erratum

Trends in the global immuno-oncology landscape   
Jun Tang, Laura Pearce, Jill O'Donnell-Tormey & Vanessa M. Hubbard-Lucey
p922 | doi:10.1038/nrd.2018.202
Full Text | PDF



Corrigenda

Expanding the medicinal chemistry synthetic toolbox   
Jonas Boström, Dean G. Brown, Robert J. Young & György M. Keserü
p922 | doi:10.1038/nrd.2018.217
Full Text | PDF



Advertisement
===================================

Register for the latest nature.com webcast

Bioengineering Custom Cell Microenvironments with Versatile Maskless Photopatterning

Register for FREE today


Sponsored by: Alvéole

==================================
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

This email has been sent to edgeblog.alerts.2011.001@gmail.com.

If you no longer wish to receive the email alerts from Nature Reviews Drug Discovery click here to unsubscribe .
If you wish to discontinue all email services from Nature Research please click here to unsubscribe .

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Macmillan Publishers Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Research | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.

Springer Nature

No comments: